Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
about
Applications of CYP450 testing in the clinical settingSimultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activitiesAuto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1AUse of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations.Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavirGeneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsThe effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.Expanding an Efficient, Electrically Driven and CNT-Tagged P450 System into the Third Dimension: A Nanowired CNT-Containing and Enzyme-Stabilising 3 D Sol-Gel Electrode.Pharmacokinetic Drug Interaction Studies with Enzalutamide.Natural health product interactions with medication.Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseasesPharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.Effect of Repeated Wuniu Early Tea Administration on the CYP450 Activity Using a Cocktail Method.Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail.In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know.Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug-Drug Interactions Involving Modafinil.Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs.Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.Use of microdose phenotyping to individualise dosing of patients.Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilutionOmeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A.Pharmacodynamics of uniform versus nonuniform warfarin dosages.Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.
P2860
Q24621760-78FB0E87-A321-4D77-981E-13319929E4BEQ28269209-DA276873-DB90-45D7-8E00-348843B332DDQ28548385-C8C5D84A-F2A7-4808-AED4-949A5255F0F8Q30482850-27898A50-9C6B-4D39-85CD-464C3FF4EE9BQ30688345-74A845A3-54C4-4906-84D9-6A30425D1B58Q33899829-24FB88DD-F096-4317-BA32-BCEAEF7E249CQ34116690-E717C280-6E96-4A7A-93CA-D6BCC3ECB7FFQ34510611-0EA30011-189E-4D13-9085-D3ACC9C05488Q35827755-19366A06-F548-451D-8C23-A8D460E5566CQ36012059-1A786197-7407-47E7-85B9-0F725267DA8DQ36087515-51BB58AB-3282-4FFD-9A8D-5AE6159AB9F6Q36278312-347C7680-8891-4002-8BD3-BE38D986F91CQ36460560-9272BF18-FBB4-4333-81D2-025DF26867E7Q36733922-9ED52D74-87FE-47B8-9D27-0AB37EC84935Q36922212-C58485D4-3E6E-4F0B-8A18-26A86FA86468Q37034724-2D18B168-244D-42D2-89EA-266432179546Q37424646-EA6F84E2-ED4E-44E7-9382-005DB87CBACEQ37622756-DB57FA74-4024-406A-BA46-8CA1812708FFQ37863679-851E8F21-CB5A-49B9-8C75-54F878FA556EQ38596987-B325C6A7-580A-4651-AA3C-8074ABE65B83Q39906127-79054079-6FC0-4840-A9CA-D84AD50BF239Q40186641-B6E1C35E-33DF-4C0B-B8AB-1AFC07273C3DQ40330877-991F5F3E-52BE-4D45-A819-94CAC0B9B45DQ40405015-469F07D9-6420-45E1-9A52-77075EF7426CQ40996401-97800C5C-27C2-48F6-BCCB-885E591266D3Q41634295-E78D2E8E-D012-493B-9A43-65073E91C861Q41737190-B24A4249-72FC-4331-8113-8F1AECE444C2Q41834120-D7C63C95-951F-403F-B38C-AA5874A71F83Q42284131-321056FA-C82E-4285-A2B8-A798331AB511Q42758567-1DBCB554-6557-4B11-B2CA-0B0E1446D427Q43626046-741F56C8-88DA-4805-9AD3-A13983088F81Q44394691-FB781CCD-DC1C-4EA0-B8DF-2FECD2486B86Q44893470-41307050-C011-47B5-BB7C-2AF83C19A7A0Q44897880-C291E059-5D73-4FC7-86C7-9CBD62B90478Q46112124-C85DB450-C291-45C9-A7A1-22B142806FE5Q46575263-174D5E57-1016-4977-8703-2048C1151856Q46807641-381DCC3F-51B6-409E-9E02-EA00EDA6E275Q47449167-BC879234-FC55-424A-AB5B-5F61A8F5DAEEQ47692758-FF55E470-604A-499B-B875-7E4A1040788EQ47925032-42FA92A8-FDFE-4D32-8EA6-3A1725268B04
P2860
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Combined phenotypic assessment ...... he "Cooperstown 5+1 cocktail".
@en
Combined phenotypic assessment ...... he "Cooperstown 5+1 cocktail".
@nl
type
label
Combined phenotypic assessment ...... he "Cooperstown 5+1 cocktail".
@en
Combined phenotypic assessment ...... he "Cooperstown 5+1 cocktail".
@nl
prefLabel
Combined phenotypic assessment ...... he "Cooperstown 5+1 cocktail".
@en
Combined phenotypic assessment ...... he "Cooperstown 5+1 cocktail".
@nl
P2093
P1476
Combined phenotypic assessment ...... he "Cooperstown 5+1 cocktail".
@en
P2093
Andrea Gaedigk
Angela D M Kashuba
Anne N Nafziger
Elizabeth Rowland
Gregory L Kearns
J Steven Leeder
Joseph S Bertino
Siwaporn Chainuvati
Yanhua Zhang
P304
P356
10.1016/S0009-9236(03)00229-7
P407
P577
2003-11-01T00:00:00Z